Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-12-12
2006-12-12
Borin, Michael (Department: 1631)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07148194
ABSTRACT:
The invention provides peptides, and compositions containing those peptides, that increase the amount of fibronectin in tissue. These compositions are useful for encouraging the maintenance and development of healthy skin, for preventing and treating wrinkles, and for treating wounds. The peptides can be formulated into therapeutic compositions, lotions, creams, skin coverings and wound dressings that facilitate healing and healthy skin development, discourage scarring and wrinkling, and ameliorate the effects of healing.
REFERENCES:
patent: 4424552 (1984-01-01), Saint Marcoux
patent: 5270447 (1993-12-01), Liotta et al.
patent: 5280106 (1994-01-01), Liotta et al.
patent: 5372809 (1994-12-01), Liotta et al.
patent: 5585356 (1996-12-01), Liotta et al.
patent: 5698671 (1997-12-01), Stetler-Stevenson et al.
patent: 5770691 (1998-06-01), Fields et al.
patent: 5811252 (1998-09-01), Verheijen
patent: 5869277 (1999-02-01), Stetler-Stevenson et al.
patent: 6043087 (2000-03-01), Bini et al.
patent: 6127139 (2000-10-01), Te Koppele et al.
patent: 6184022 (2001-02-01), Seiki et al.
patent: 6191225 (2001-02-01), Barkac et al.
patent: 6204043 (2001-03-01), Shapiro
patent: 6274703 (2001-08-01), Goldberg
patent: 6399371 (2002-06-01), Falduto et al.
patent: 6482802 (2002-11-01), Hu et al.
patent: 6753310 (2004-06-01), Oku et al.
patent: 6812339 (2004-11-01), Venter et al.
patent: 2001/0016333 (2001-08-01), Seki et al.
patent: 2001/0031478 (2001-10-01), Bronstein et al.
patent: 2002/0099004 (2002-07-01), Lund
patent: 2003/0012794 (2003-01-01), Srivastava et al.
patent: 2003/0096757 (2003-05-01), Quirk et al.
patent: 2003/0166567 (2003-09-01), Quirk et al.
patent: 2003/0199440 (2003-10-01), Dack et al.
patent: 2004/0010001 (2004-01-01), Au et al.
patent: 2004/0259802 (2004-12-01), Yang et al.
patent: 0917165 (1999-05-01), None
patent: 06213888 (1994-05-01), None
patent: 06300757 (1994-10-01), None
patent: 07159402 (1995-06-01), None
patent: 07303482 (1995-11-01), None
patent: 07330795 (1995-12-01), None
patent: 08134098 (1996-05-01), None
patent: 08136548 (1996-05-01), None
patent: 08217800 (1996-08-01), None
patent: 09023889 (1997-01-01), None
patent: 09084589 (1997-03-01), None
patent: 09087299 (1997-03-01), None
patent: 09136841 (1997-05-01), None
patent: 09206099 (1997-08-01), None
patent: 09249700 (1997-09-01), None
patent: 10210982 (1998-08-01), None
patent: 10287700 (1998-10-01), None
patent: 10313896 (1998-12-01), None
patent: 2000270874 (2000-10-01), None
patent: 2001011093 (2001-01-01), None
patent: 2001072589 (2001-03-01), None
patent: WO-90/10228 (1990-09-01), None
patent: WO-94/10208 (1994-05-01), None
patent: WO-95/02045 (1995-01-01), None
patent: WO-95/5374 (1995-06-01), None
patent: WO 96/18725 (1996-06-01), None
patent: WO 97/25437 (1997-07-01), None
patent: WO-98/04287 (1998-02-01), None
patent: WO-98/12309 (1998-03-01), None
patent: WO-98/31818 (1998-07-01), None
patent: WO-98/34641 (1998-08-01), None
patent: WO-98/40475 (1998-09-01), None
patent: WO-98/42865 (1998-10-01), None
patent: WO-99/05261 (1999-02-01), None
patent: WO 99/31969 (1999-07-01), None
patent: WO-99/58126 (1999-11-01), None
patent: WO 99/65519 (1999-12-01), None
patent: WO-00/20860 (2000-04-01), None
patent: WO-00/63227 (2000-10-01), None
patent: WO-00/74634 (2000-12-01), None
patent: WO-01/10437 (2001-02-01), None
patent: WO-01/13937 (2001-03-01), None
patent: WO-01/38558 (2001-05-01), None
patent: WO-01/54723 (2001-08-01), None
patent: WO-01/62206 (2001-08-01), None
patent: WO-01/62261 (2001-08-01), None
patent: WO-00/53219 (2001-09-01), None
patent: WO-03/018748 (2003-03-01), None
Agren, Magnus S., “Matirx metalloproteinases (MMPs) are required for re-epitheliazation of cutaneous wounds”,Archives Dermatol Res, 291, (1999), 583-590.
Becker, Joseph W., et al., “Stromelysin-1: Three-dimensional structure of the inhibited catalytic domain and of the C-truncated proenzyme”,Protein Science, 4, (1995), 1966-1976.
Brown, Rebeccah L., et al., “PDGF and TGF-a Act Synergistically to Improve Wound Healing in the Genetically Diabetic Mouse”,Journal of Surgical Research, 56, (1994), 562-570.
Browner, Michelle F., et al., “Matrilysin-Inhibitor Complexes: Common Themes among Metalloproteases”,Biochemistry, 34, (1995), 6602-6610.
Calabrese, Edward J., “Cell Migration / Chemotaxis: Biphasic Dose Responses”,Critical Reviews in Toxicology, 31 (4&5), (2001), 615-624.
Calvin, Melissa, “Cutaneous Wound Repair”,Wounds: A Compendium of Clinical Research and Practice, 10 (1), (1998), 12-32.
Chi, Yeon Sook, et al., “Effects of the Chestnut Inner Shell Extract on the Expression of Adhesion Molecules, Fibronectin and Vitronectin, of Skin Fibroblasts in Culture”,Archives of Pharmacal Research, 25 (4), (2002), 469-474.
Clark, Richard A., “Wound Repair”,The Molecular and Cellular Bilogy of Wound Repair—2nd. ed., Plenum Press, NY, (1995), 3-50.
Colandrea, Teresa D., et al., “Epidermal Expression of Collagenase Delays Wound-Healing in Transgenic Mice”,The Journal of Investigative Dermatology, (1998), 1029-1033.
Duivenvoorden, Wilhelmina C., et al., “Use of Tetracycline as an Inhibitor of Matrix Metalloproteinase Activity Secreted by Human Bone-Metastasizing Cancer Cells”,Invasion Metastasis, (1997), 312-322.
Fernandez-Catalan, Carlos , et al., “Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibiotr of metalloproteinases-2, the soluble progelatinase A receptor”,The EMBO Journal, 17 (17), (1998), 5238-5248.
Freire, E. , et al., “Calorimentrically Determined Dynamics Of Complex Unfolding Transitions in Proteins”,Annual Review of Biophysics and Biophysical Chemistry, 19, (1990), 159-188.
Gomis-Ruth, Franz-Xaver, et al., “Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1”,Letters to Nature, 389, (1997), 77-81.
Grams, Frank, et al., “X-ray structures of human neutrophil collagenase complexed with peptide hydrozamate and peptide thiol inhibitors”,European Journal of Biochemistry, 228, (1995), 830-841.
Guex, Nicolas, et al., “Swiss-MODEL and the Swiss-Pdb Viewer: An environment for comparative protein modeling”,Electrophesis, 18, (1997), 2714-2723.
Higgins, Desmond G., et al., “Clustal V: improved software for multiple sequence alignment”,Computer applications in the biosciences, 8 (2), (1992), 189-191.
Howard, Eric W., et al., “Preferential Inhibition of 72- and 92-kDa Gelatinases by Tissue Inhibitor of Metalloproteinases-2”,The Journal of Biological Chemistry, 266 (20), (1991), 13070-13075.
Huang, Wen, et al., “Folding and characterization of the amino-terminal domain of human tissue inhibitor of metalloproteinases-1 (TIMP-1) expressed at high yield inE. coli”, FEBS Letters, 384, (1996), 155-161.
Karlsson, Robert, et al., “Experimental Design for Kinetic Analysis of Protein—Protein Interactions with surface plasmon resonance biosensors”,Journal of Immunological Methods, 200, (1997), 121-133.
Lakowicz, Joseph R., “Energy Transfer”,Principles of Fluorescence Spectroscopy, Chapter 10,(1983), 303-339.
Levit, Shimon, et al., “Ribonucleas S-Peptide”,The Journal of Biological Chemistry, 251 (5), (1976), 1333-1339.
Levy, Daniel E., et al., “Martrix Metalloproteinase Inhibitors: A Structure-Activity Study”,Journal of Medicinal Chemistry, 41, (1998), 199-223.
Li, J , et al., “Structure of full-length porcine synovial collagenase reveals a C-terminal domain containing a calcium-linked, four-bladed b-propeller”,Structure, 3 (6), (1995), 541-549.
Libson, Andrew M., et al., “Crystal structure of the haemopexin-like C-terminal domain of gelatinase A”,Nature Structural Biology, 2 (11), (1995), 938-942.
Lofas, Stefan, et al., “Dextran modified gold for surfaces for surface plasmon resonance sensors: immunoreacti
Malik Sohail
Quirk Stephen
Borin Michael
Kimberly--Clark Worldwide, Inc.
Schwegman Lundberg Woessner & Kluth P.A.
LandOfFree
Method to increase fibronectin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method to increase fibronectin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method to increase fibronectin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3712646